29 October 2021 at 3:00 p.m. (EEST)
The Board of Directors of Nightingale Health Plc has in its meeting on September 30, 2021 and October 7, 2021, approved request of shareholders to convert 538,006 Series A shares and 454,054 EMP shares of Nightingale Health Plc to Series B shares in accordance with Article 5 in the Articles of Association.
As a result of conversion of shares, the number of the Company’s Series A shares is 22,179,668, Series B shares is 37,219,489 and EMP shares is 1,482,580. The conversion does not affect the total amount of shares which is 60,881,737. The number of votes of the company's shares is after the conversion 259,016,169.
The conversions of shares were registered in the Trade Register on October 29, 2021. The converted shares will be listed on the Nasdaq First North Growth Market Finland marketplace together with the old shares as of November 1, 2021.
For further information, please contact:
Teemu Suna, CEO
Oaklins Merasco Ltd, tel. +358 9 6129 670
Nightingale Health is a health technology company transforming preventive care. We envisage a world that focuses on keeping people healthy rather than just treating illnesses. The wide-ranging disease risk predictions provided by Nightingale consist of two interconnected factors: The extensive blood analysis technology developed by Nightingale and a large amount of data on health events. Nightingale helps people make better personal health decisions and connects the health industry to offer their services for individuals’ preventative needs. By empowering the world with comprehensive health insights, we accelerate scientific discoveries, industry developments and improve personal health for everyone.